Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies

BACKGROUND: CC‐90011 is an oral, potent, selective, reversible inhibitor of lysine‐specific demethylase 1 (LSD1) that was well tolerated, with encouraging activity in patients who had advanced solid tumors or relapsed/refractory marginal zone lymphoma. The authors present long‐term safety and effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Niccoli, Patricia, Capdevila, Jaume, Curigliano, Giuseppe, Moreno, Victor, de Braud, Filippo, de Villambrosia, Sonia Gonzalez, Martin‐Romano, Patricia, Baudin, Eric, Arias, Marina, de Alvaro, Juan, Parra‐Palau, Josep L., Sánchez‐Pérez, Tania, Aronchik, Ida, Filvaroff, Ellen H., Lamba, Manisha, Nikolova, Zariana, de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540525/
https://www.ncbi.nlm.nih.gov/pubmed/35737639
http://dx.doi.org/10.1002/cncr.34366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540525/
https://www.ncbi.nlm.nih.gov/pubmed/35737639
http://dx.doi.org/10.1002/cncr.34366

Ejemplares similares